NetworkNewsBreaks

WednesdayJan 13, 2021 10:07 am

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.074M in Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, priced at-the-market under Nasdaq rules. Predictive Oncology secured $3.074 million in gross proceeds from the offering. In a concurrent private placement, Predictive Oncology also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,825,420 shares of common stock at an exercise price of $0.80 per share. H.C. Wainwright & Co.…

Continue Reading

WednesdayJan 13, 2021 9:46 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA approval to begin clinical trials studying the company’s lead drug candidate, Berubicin. CNSP is developing Berubicin as a potential treatment for glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Climaco called Berubicin…

Continue Reading

WednesdayJan 13, 2021 9:20 am

NetworkNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Secures $5.1M in Underwritten Public Offering

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial metal 3D printing industry, has announced the closing of its previously disclosed underwritten public offering of 1,488,507 shares of common stock, each at a public offering price of $3.00. In connection with the offering, the underwriter exercised in full its over-allotment option to purchase an additional 223,276 shares of common stock at the public offering price, less the underwriting discount. Sigma Labs secured $5,135,349 in gross proceeds from the offering consisting of 1,711,783 shares. H.C. Wainwright & Co. acted as the sole book-running manager for the…

Continue Reading

TuesdayJan 12, 2021 1:46 pm

NetworkNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Leverages Key Experience, Prepares Entry into Psychedelic Mushroom Market

Pure Extracts (CSE: PULL), a plant-based extraction company, is focused on cannabis, hemp, and functional mushroom sectors, the last of which is projected to rise to a value of $34.4 billion by the end of 2024. Seeking to capitalize on the growing interest within the sector, Pure Extracts has expanded its business model to include mushroom formulations using extraction processes proven compatible with the company’s existing infrastructure. Working alongside its scientific advisor—Dr. Alexander MacGregor, founder of the Toronto Institute of Pharmaceutical Technology—Pure Extracts intends to develop high bio-available products and novel delivery methodologies, which will include tinctures, pills, capsules and…

Continue Reading

TuesdayJan 12, 2021 12:58 pm

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient outcomes. A recent article discussing this reads, “POAI realizes that ‘just genomics’ is not enough to deliver personalized therapeutic options. The company believes that a multi-omic approach to disease, or one that gathers data from…

Continue Reading

TuesdayJan 12, 2021 12:47 pm

NetworkNewsBreaks – InsuraGuest Technologies Inc. (TSXV: ISGI) Poised to Further Cement Leading Position in InsureTech Market

InsuraGuest Technologies (TSXV: ISGI) is continuing to revolutionize the insurance industry by harnessing the power of its proprietary software platform to deliver digital insurance across multiple sectors. The company, through its wholly owned subsidiary InsuraGuest Inc., recently signed another Agent Producer Agreement that will allow it to extend the reach of its novel Hospitality Liability Coverage to more hotel and vacation rental properties. The latest agreement is with Foundation Risk Partners, one of the fastest-growing insurance brokerage and consulting firms in the United States, which will begin to provide InsuraGuest’s Hospitality Liability coverage to its U.S. hotel clients. The strategic…

Continue Reading

TuesdayJan 12, 2021 12:08 pm

NetworkNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL) Announces Strategic Engagements

Kaival Brands (OTCQB: KAVL), a company focused on generating stockholder value by incubating innovative products into mature and dominant brands within their respective markets, today announced new engagements of both Morgan Lewis and Spencer Stuart. According to the update, the company believes that these engagements will allow it to continue its expansion and assist in reaching its next iterative stage of growth. “We have enjoyed tremendous revenue growth in a rapid fashion,” said CEO Niraj Patel. “We are now in a position to build the appropriate infrastructure to match our current and aspirational revenue targets.” To view the full press…

Continue Reading

TuesdayJan 12, 2021 11:47 am

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX), First Wave, Receive Notice of Allowance for Niclosamide Patent

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, announced that it, along with First Wave Bio Inc., has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”). The notice of allowance is for issuance of a patent that covers use of niclosamide as a treatment for COVID-19-associated GI disease. AZRX filed the patent with First Wave, a clinical-stage biotechnology company developing novel gut-targeted small molecules for inflammatory bowel disease and other serious conditions. GI infections have become a significant unmet clinical need during the…

Continue Reading

TuesdayJan 12, 2021 11:22 am

NetworkNewsBreaks – PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA) Hires Jon Lamb to Serve as President of North American Operations

PowerBand Solutions (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA), an innovative automotive fintech leader providing digital and virtual platform solutions, today announced the appointment of Jon Lamb to one of the company's top executive leadership roles as president of North American Operations. Lamb has founded and served as CEO and president of numerous successful business entities and is a patent author and mission-driven investor. Jon serves as an active board member and advisor to multiple ad tech and fintech organizations. "Filling the critical role of president of North American operations was a major decision for the company,” said Kelly Jennings, CEO…

Continue Reading

TuesdayJan 12, 2021 11:01 am

NetworkNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) Becomes One of First Publicly Traded Companies to Receive USDA Organic Certification for CBD Tinctures

HempFusion Wellness (TSX: CBD.U), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has received USDA Organic Certification for its HempFusion CBD tinctures; the exclusive line of tinctures offers products with potency from 150mg (5mg per serving) to 1,500mg (50mg per serving) of CBD per bottle. HempFusion is one of the first publicly traded CBD companies to receive the certification; the distinction is significant because organic products generally represent some of the highest quality products available. The process to certify its tinctures as USDA Organic started in 2018, and involve providing detailed documentation for every…

Continue Reading